Zynerba's ZYN002 misses in Phase II for epilepsy

Zynerba Pharmaceuticals Inc.(NASDAQ:ZYNE) reported top-line data from the Phase II STAR 1 trial in 188 patients with refractory epilepsy showing that 97.5 and 195 mg doses of ZYN002 every 12 hours each missed the primary endpoint of improving the median percent reduction in focal seizure frequency from baseline to week 12 vs. placebo (18.4% and 14%, respectively, vs. 8.7%). Both doses of ZYN002 also missed the secondary endpoints of improving the proportion of patients with a ≥50% reduction from baseline in seizure frequency, percent change from baseline in seizure frequency and number of seizure-free days vs. placebo. ZYN002 was well tolerated with no treatment-related serious adverse events reported.

The double-blind, Australian and New Zealand trial enrolled adults with confirmed refractory epilepsy with focal seizures with or without secondary generalization...